The global oral antibiotics market is expected to grow at a CAGR of 2.7% from 2019 to 2027, reaching $23,306.10 million by 2027. Antibiotics are used to treat bacterial infections and sometimes protozoan infections by either stopping bacterial growth or killing bacteria directly. There are various types of antibiotics available and are used in various medical procedures such as transplants, dialysis, weakened immune system, and joint replacements.
The demand for antibiotics is rising due to higher consumption in low- and middle-income countries and an increase in infectious diseases. The development of new antibiotics to treat bacterial infections and numerous clinical trials are also driving market growth. However, the growth of the market is hindered by the development of antibiotic resistance caused by misusing antibiotics and regulatory approval time. Nevertheless, the discovery of new prospect molecules and combination therapies to treat antibiotic-resistant infections is expected to offer significant profit opportunities for market players.
Get a PDF Sample of the Oral Antibiotics Market : https://www.alliedmarketresearch.com/request-sample/6905
Key Market Players : ABBOTT LABORATORIES, ALLERGAN PLC, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, MERCK & CO., INC., MYLAN N.V., NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.), PFIZER INC., SANOFI, TEVA PHARMACEUTICAL INDUSTRIES LTD.
Oral Antibiotics Market Report Highlights :
By Class :
Beta Lactam and Beta Lactamase Inhibitors
Penicillin
Broad-spectrum penicillin
Mid/Narrow Spectrum Penicillin
Cephalosporin
Others
Quinolone
Macrolide
Others
By Application :
Community-acquired respiratory tract infections (CARTIs)
Upper Respiratory Tract Infections (URTI)
Lower Respiratory Tract Infections (LRTIs)
Urinary tract infections (UTIs)
Dental
Combination
Monotherapies
Others
BY DRUG ORIGIN :
Natural
Semisynthetic
Synthetic
By Spectrum Of Activity
Broad-spectrum Antibiotic
Mid/Narrow-spectrum antibiotic